Results 11 to 20 of about 489 (130)

Pharmacokinetics, disposition, and biotransformation of the cardiac myosin inhibitor aficamten in humans [PDF]

Pharmacology Research & Perspectives
Aficamten, a cardiac myosin inhibitor, is being developed for the treatment of patients with symptomatic hypertrophic cardiomyopathy (HCM). The purpose of this study was to determine the absorption, metabolism, and excretion of aficamten.
Donghong Xu, Punag Divanji, Adrienne Griffith, Rajaa Sukhun, Kathleen Cheplo, Jianlin Li, Polina German   +6 more
doaj   +5 more sources

Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical Trial. [PDF]

JAMA Cardiol
Importance: Impaired exercise capacity is a cardinal manifestation of obstructive hypertrophic cardiomyopathy (HCM). The Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Obstructive HCM ...
Lee MMY, Masri A, Nassif ME, Barriales-Villa R, Abraham TP, Claggett BL, Coats CJ, Gimeno JR, Kulac IJ, Landsteiner I, Ma C, Maron MS, Olivotto I, Owens AT, Solomon SD, Veselka J, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Lewis GD, SEQUOIA-HCM Investigators.   +23 more
europepmc   +11 more sources

Efficacy of aficamten in obstructive hypertrophic cardiomyopathy: A systematic review and meta-analysis [PDF]

American Heart Journal Plus
Background: Obstructive hypertrophic cardiomyopathy (oHCM), a morbid hereditary condition, is characterized by asymmetrical intraventricular septum enlargement, obstructing blood flow from the left ventricle outflow tract (LVOT) and lowering cardiac ...
Muhammad Nabeel Saddique, Hamza Irfan, Saad Ashraf, Maria Qadri, Hammad Javaid, Sana Iftikhar, Muhammad Zain ul Haq, Laveeza Fatima, Qasim Mehmood, Anurag Jha, Saad Masood, Muhammad Safiullah, Muhammad Imaz Bhatti, Sheena Shamoon, Javed Iqbal   +14 more
doaj   +4 more sources

Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial. [PDF]

Eur Heart J
Background and Aims: The role of biomarker testing in the management of obstructive hypertrophic cardiomyopathy is not well defined. This pre-specified analysis of SEQUOIA-HCM (NCT05186818) sought to define the associations between clinical ...
Coats CJ, Masri A, Barriales-Villa R, Abraham TP, Brinkley DM, Claggett BL, Hagege A, Hegde SM, Ho CY, Kulac IJ, Lee MMY, Maron MS, Olivotto I, Owens AT, Solomon SD, Tfelt-Hansen J, Watkins H, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Januzzi JL.   +23 more
europepmc   +12 more sources

Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy [PDF]

Journal of the American College of Cardiology, 2023
Background: Left ventricular outflow tract (LVOT) obstruction is a major determinant of heart failure symptoms in obstructive hypertrophic cardiomyopathy (oHCM).
Olivotto, Iacopo
core   +8 more sources

Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM. [PDF]

J Am Coll Cardiol
Background: A primary goal in treating obstructive hypertrophic cardiomyopathy (oHCM) is to improve patients’ health status: their symptoms, function, and quality of life. The health status benefits of aficamten, a novel cardiac myosin inhibitor, have not been comprehensively described. Objectives: This study sought to determine the effect of aficamten
Sherrod CF, Saberi S, Nassif ME, Claggett BL, Coats CJ, Garcia-Pavia P, Januzzi JL, Lewis GD, Ma C, Maron MS, Miao ZM, Olivotto I, Veselka J, Butzner M, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Spertus JA.   +20 more
europepmc   +5 more sources

Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy [PDF]

JACC: Heart Failure
Background Disopyramide, used in obstructive hypertrophic cardiomyopathy (oHCM) for its negative inotropic properties mediated by its reduction in cytosolic calcium, has been recommended for decades as an option to relieve resistant obstruction ...
Olivotto, Iacopo
core   +7 more sources

Precision Negative Inotropy: The Rise of Cardiac Myosin Inhibitors in HCM [PDF]

Journal of Education, Health and Sport
Background: Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, marked by left-ventricular hypertrophy, dynamic outflow obstruction in many patients, diastolic dysfunction, and elevated risks of atrial fibrillation and heart ...
Katarzyna Skibicka, Tomasz Skibicki, Weronika Wesołowska, Robert Bujak   +3 more
doaj   +3 more sources

A New Era in the Management of Hypertrophic Cardiomyopathy. [PDF]

Rev Cardiovasc Med
Hypertrophic cardiomyopathy (HCM) is a prevalent cardiac disease characterized by marked phenotypic variability. Recent advances in diagnosis and treatment have allowed a personalized approach to the treatment of this disease.
Perez-Asensio A, Llamas-Gomez H, Lara-Palomo A, Villar-Ruiz A, Jimenez-Mendez C, Palomino-Doza J.   +5 more
europepmc   +3 more sources

Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM [PDF]

Journal of the American College of Cardiology
Background: Aficamten is a cardiac myosin inhibitor that mitigates left ventricular outflow gradients in obstructive hypertrophic cardiomyopathy (oHCM). The clinical efficacy of aficamten across multiple outcome domains in oHCM has not been fully defined.
Olivotto, Iacopo
core   +7 more sources